Increased Overall Survival Linked With Investment in Public Welfare for Black Patients With Cancer

Article

Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.

The 5-year overall survival (OS) has increased based on results from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) cancer database which showed an investment in public welfare programs, according to a study of records presented at a press briefing ahead of the 2022 American Society of Clinical Oncology Annual Meeting.1

Five-year OS was 10.8% lower among Black patients compared with Whites. However, investigators found that 5-year OS was higher for Black patients in states with greater welfare spending.

The results showed that there was a 4.55% reduction of the 5-year OS disparity in non-Hispanic Black patients compared with white patients per every 10% increase in spending. Investigators noted that the results were similar after accounting for state Medicaid eligibility limits and after excluding data related to Medicaid expansions.

“These data are thought provoking, but they are certainly not the end,” said Justin M. Barnes, MD, a radiation oncologist at Washington University of Medicine in St. Louis, Missouri, during a press briefing ahead of the 2022 ASCO Annual Meeting. “I see these data as a proof-of-concept project, some sort of public welfare investment seems to be helping improve oncologic outcomes for some of our most socioeconomically at-risk patients.”

Among patients with breast cancer, increased public welfare spending led to a 6.15% survival increase for Black patients and a 39% closing of the disparity with white patients. Patients with cervical (11.9% and 46%), colorectal (4.42% and 48%), head and neck (9.41% and 38%), liver (7.02% and 49%), ovarian (8.95% and 41%), bladder (8.18% and 44%), and uterine cancers (14.1% and 40%) also experienced a survival increase and a lessened disparity as a result of increased spending.2

Past study results have highlighted associations between cancer outcomes and social determinants of health, such as financial stability, education, place of residence, and insurance status. Additionally, research has shown that racial disparities in cancer outcomes are probably related to systemic racism that has led to adverse conditions for Black Americans and other patients of color.

Barnes and colleagues analyzed data on more than 2.9 million adult patients with newly diagnosed cancers collected in the SEER database between 2007 and 2016. State annual spending data was obtained from the United States Census Bureau and included the percentage of total public welfare spending. The primary end point of the study was 5-year OS.

Investigators performed data analysis using cluster-robust regression to account for within-state correlations. Covariates consisted of state public welfare spending, age, race/ethnicity, sex, metropolitan residence, county-level income and education, insurance, state-level poverty, state, cancer site/type, and stage at diagnosis.

“This study underscores the critical role that state social welfare spending, including Medicaid expansion, plays in reducing cancer outcome disparities,” ASCO Chief Medical Officer and Executive Vice President Julie R. Gralow, MD, the 2021 Giants of Cancer Care® award winner in the community outreach/cancer policy category, said in a news release. “State-funded programs can reduce barriers to accessing cancer care and impact survival.”

References

  1. Barnes JM, Johnston KJ, Osazuwa-Peters N. State public welfare spending and racial/ethnic disparities in overall survival among adults with cancer. Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL. Abstract 6509.
  2. A study examining the association between Medicaid and other social services spending on racial and ethnic disparities and overall survival for newly diagnosed patients with cancer. News release. ASCO. May 26, 2022. Accessed May 26, 2022.
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content